Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice in Sweden

NCT02468102 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT02468102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02468102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice in Sweden
Lead sponsor
Bayer
Phase
Observational
Overall status
Completed
Start date
June 15, 2015
Completion date
September 30, 2020
Enrollment
99,999 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, atrial fibrillation, pulmonary embolism, venous thrombosis